S&P 500   4,655.27
DOW   35,135.94
QQQ   399.69
S&P 500   4,655.27
DOW   35,135.94
QQQ   399.69
S&P 500   4,655.27
DOW   35,135.94
QQQ   399.69
S&P 500   4,655.27
DOW   35,135.94
QQQ   399.69
NASDAQ:FATE

Fate Therapeutics Stock Forecast, Price & News

$51.77
-0.75 (-1.43%)
(As of 11/29/2021 04:00 PM ET)
Add
Compare
Today's Range
$51.56
$53.66
50-Day Range
$51.77
$68.89
52-Week Range
$48.31
$121.16
Volume
619,280 shs
Average Volume
1.01 million shs
Market Capitalization
$4.94 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.52
30 days | 90 days | 365 days | Advanced Chart
Receive FATE News and Ratings via Email

Sign-up to receive the latest news and ratings for Fate Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


Fate Therapeutics logo

About Fate Therapeutics

Fate Therapeutics, Inc. engages in the development of programmed cellular immunotherapies for cancer and immune disorder. Its pipeline of products includes immuno-ocology candidates and immuno-regulation candidates. The company was founded by Philip Beachy, Sheng Ding, Rudolf Jaenisch, Randall T. Moon, Michael Rudnicki, David Scadden, Leonard Zon, Alexander Rives, Scott Wolchko, and John D. Mendlein on April 27, 2007 and is headquartered in San Diego, CA.

Headlines

Fate Therapeutics Enters Oversold Territory (FATE)
September 30, 2021 |  nasdaq.com
See More Headlines

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:FATE
Fax
N/A
Employees
279
Year Founded
N/A

Sales & Book Value

Annual Sales
$31.43 million
Book Value
$7.65 per share

Profitability

Net Income
$-173.39 million
Net Margins
-359.66%
Pretax Margin
-359.65%

Debt

Price-To-Earnings

Miscellaneous

Free Float
77,751,000
Market Cap
$4.94 billion
Optionable
Optionable

Company Calendar

Last Earnings
11/04/2021
Today
11/30/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
2/23/2022

MarketRank

Overall MarketRank

2.33 out of 5 stars

Medical Sector

249th out of 1,392 stocks

Biological Products, Except Diagnostic Industry

42nd out of 201 stocks

Analyst Opinion: 3.4Community Rank: 4.9Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.0 5 -4 -3 -2 -1 -












Fate Therapeutics (NASDAQ:FATE) Frequently Asked Questions

Is Fate Therapeutics a buy right now?

16 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Fate Therapeutics in the last twelve months. There are currently 4 hold ratings and 12 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Fate Therapeutics stock.
View analyst ratings for Fate Therapeutics
or view top-rated stocks.

How has Fate Therapeutics' stock been impacted by Coronavirus (COVID-19)?

Fate Therapeutics' stock was trading at $23.79 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, FATE stock has increased by 117.6% and is now trading at $51.77.
View which stocks have been most impacted by COVID-19
.

When is Fate Therapeutics' next earnings date?

Fate Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, February 23rd 2022.
View our earnings forecast for Fate Therapeutics
.

How were Fate Therapeutics' earnings last quarter?

Fate Therapeutics, Inc. (NASDAQ:FATE) issued its earnings results on Thursday, November, 4th. The biopharmaceutical company reported ($0.45) earnings per share for the quarter, topping the consensus estimate of ($0.58) by $0.13. The biopharmaceutical company had revenue of $14.23 million for the quarter, compared to analyst estimates of $8.67 million. Fate Therapeutics had a negative net margin of 359.66% and a negative trailing twelve-month return on equity of 28.25%. The business's quarterly revenue was up 88.3% on a year-over-year basis. During the same period in the prior year, the company posted ($0.36) earnings per share.
View Fate Therapeutics' earnings history
.

What price target have analysts set for FATE?

16 Wall Street analysts have issued 12 month target prices for Fate Therapeutics' stock. Their forecasts range from $60.00 to $145.00. On average, they expect Fate Therapeutics' stock price to reach $107.83 in the next twelve months. This suggests a possible upside of 108.3% from the stock's current price.
View analysts' price targets for Fate Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Fate Therapeutics' key executives?

Fate Therapeutics' management team includes the following people:

What is Scott Wolchko's approval rating as Fate Therapeutics' CEO?

2 employees have rated Fate Therapeutics CEO Scott Wolchko on Glassdoor.com. Scott Wolchko has an approval rating of 100% among Fate Therapeutics' employees. This puts Scott Wolchko in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Fate Therapeutics own?

What is Fate Therapeutics' stock symbol?

Fate Therapeutics trades on the NASDAQ under the ticker symbol "FATE."

Who are Fate Therapeutics' major shareholders?

Fate Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (7.01%), Johnson & Johnson (3.54%), Bellevue Group AG (3.39%), Farallon Capital Management LLC (2.42%), Lone Pine Capital LLC (2.30%) and Janus Henderson Group PLC (1.80%). Company insiders that own Fate Therapeutics stock include Bahram Valamehr, Cindy Tahl, Daniel D Shoemaker, Edward J Dulac III, J Scott Wolchko, Louis T Petrillo, Redmile Group, Llc and Yu-Waye Chu.
View institutional ownership trends for Fate Therapeutics
.

Which institutional investors are selling Fate Therapeutics stock?

FATE stock was sold by a variety of institutional investors in the last quarter, including Invesco Ltd., Victory Capital Management Inc., Jennison Associates LLC, Assenagon Asset Management S.A., Two Sigma Advisers LP, Royal Bank of Canada, Janus Henderson Group PLC, and Principal Financial Group Inc.. Company insiders that have sold Fate Therapeutics company stock in the last year include Bahram Valamehr, Cindy Tahl, Daniel D Shoemaker, Edward J Dulac III, J Scott Wolchko, Louis T Petrillo, and Yu-Waye Chu.
View insider buying and selling activity for Fate Therapeutics
or view top insider-selling stocks.

Which institutional investors are buying Fate Therapeutics stock?

FATE stock was purchased by a variety of institutional investors in the last quarter, including Johnson & Johnson, Bellevue Group AG, Lone Pine Capital LLC, Farallon Capital Management LLC, Wellington Management Group LLP, Nikko Asset Management Americas Inc., Sumitomo Mitsui Trust Holdings Inc., and Dimensional Fund Advisors LP.
View insider buying and selling activity for Fate Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Fate Therapeutics?

Shares of FATE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Fate Therapeutics' stock price today?

One share of FATE stock can currently be purchased for approximately $51.77.

How much money does Fate Therapeutics make?

Fate Therapeutics has a market capitalization of $4.94 billion and generates $31.43 million in revenue each year. The biopharmaceutical company earns $-173.39 million in net income (profit) each year or ($2.12) on an earnings per share basis.

How many employees does Fate Therapeutics have?

Fate Therapeutics employs 279 workers across the globe.

What is Fate Therapeutics' official website?

The official website for Fate Therapeutics is www.fatetherapeutics.com.

Where are Fate Therapeutics' headquarters?

Fate Therapeutics is headquartered at 3535 GENERAL ATOMICS COURT SUITE 200, SAN DIEGO CA, 92121.

How can I contact Fate Therapeutics?

Fate Therapeutics' mailing address is 3535 GENERAL ATOMICS COURT SUITE 200, SAN DIEGO CA, 92121. The biopharmaceutical company can be reached via phone at (858) 875-1800 or via email at [email protected].


This page was last updated on 11/30/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.